The Leukemia & Lymphoma Society (LLS) today announced it has committed $28.6 million in new research investment to advance the most promising blood cancer science at leading academic and medical institutions around the world, including Dana-Farber Cancer Institute, Weill Cornell Medical College and MD Anderson Cancer Center. As LLS leads the charge to find cures for cancer patients, this new funding, along with ongoing investment in LLS’s aggressive research agenda, brings LLS’s total commitment to blood cancer research to more than $1 billion. The investment has led to the development of nearly every therapy currently used to treat the blood cancers.
Along with these new research grants, LLS remains committed to collaborating with biotechnology companies through its innovative Therapy Acceleration Program® (TAP), a model pioneered by LLS in the cancer arena in recognition that traditional research approaches weren’t yielding treatments and cures fast enough for patients. LLS commits approximately $13 million a year to its TAP initiatives. As part of the 24 current such collaborations, LLS recently initiated new investments with Kite Pharma and OncoPep.
To view the multimedia release go to:
http://www.multivu.com/players/English/7554852-lls-cancer-research-funding/
Boston Scientific (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) approval for the SYNERGY™ Bioabsorbable Polymer Drug-Eluting Stent System (BP-DES) for the treatment of coronary artery disease.
With this FDA approval, Boston Scientific will commence commercialization of the first and only BP-DES in the U.S. Notably, both the drug coating and the polymer – which modulates drug release – are fully absorbed shortly after drug elution is complete at three months.
The SYNERGY Stent provides synchronized drug and polymer absorption. It is designed to enable more rapid and complete arterial healing, and to thereby reduce the risk of complications associated with long-term polymer exposure compared to currently-used drug-eluting stents (DES) with permanent polymers.
To view the multimedia release go to:
http://www.multivu.com/players/English/7223456-boston-scientific-fda-approval-synergy/
As a founding voice in the world of holistic wellness, Canyon Ranch® has the wisdom and expertise of spending nearly 40 years helping its guests achieve well-being. Now, the life-enhancement brand that’s built a devoted global following, is finally going global itself.
Under the guidance of the brand’s new Chief Executive Officer, Susan E. Docherty, the Company announced today the development of its first-ever international destination, Canyon Ranch Wellness Resort at Kaplankaya, on a spectacular peninsula of the sun-kissed Aegean coast. The initial phase of the Canyon Ranch development, which will open in July 2016, will include a strikingly modern resort and luxury real estate offerings. The property will integrate the signature wellness and lifestyle programming that has earned Canyon Ranch a famously loyal clientele worldwide.
To view the multimedia release go to:
http://www.multivu.com/players/English/7634751-canyon-ranch-resort-kaplankaya-turkey/
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
The largest candy-consumption night of the year is right around the corner. More than 80 percent of parents say their kids will participate in a Halloween celebration (2), and when asked about concerns related to Halloween, more than two-thirds of parents say they are worried about their children’s teeth, according to a recent Ad Council survey (1). However, three out of four parents report that their kids sometimes or frequently forget to brush their teeth on a daily basis. With cavities being a top concern, the Kids’ Healthy Mouths campaign is celebrating National Brush Day® on Sunday, November 1, the day after Halloween, to emphasize the importance of brushing for two minutes, twice a day, every day.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7676151-kids-healthy-mouths-ad-council-brush-day/
(1), (2) The Ad Council’s survey was conducted by LightSpeed Research in September 2014. The nationally representative online survey included 600 parents with children 0-12.
From a child development expert whose pet-centric curriculum is helping rehabilitate troubled adolescents to the founder of New York City’s first cat café, Purina’s third Better With Pets Summit showcased how the relationship between pets and people enhances overall emotional wellness.
The day-long summit, which was hosted by Emmy-nominated comedian and writer, Josh Gondelman, took place at the Brooklyn Expo Center in New York City on Nov. 3 and featured three panel discussions that examined the emotional relationship between pets and people, including the reciprocal effects both have on one another. Keynote speeches were presented by Purina senior research nutritionist Arleigh Reynolds, who has researched the dog and human bond for many years in Alaska and supports of The Frank Attla Youth Program; and author and reality television personality Carole Radziwill, who shared how pet ownership has shaped her life experiences.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7655851-purina-better-with-pets-summit/
The United Nations Foundation’s Shot@Life campaign marks World Pneumonia Day, November 12, by asking Americans to raise awareness, funds and advocate to members of Congress to support global immunization programs. Pneumonia kills nearly a million children under the age of five each year and almost half of those deaths are vaccine-preventable.
“Around the world one in five children lack access to the vaccines they need,” said Devi Thomas, Director, UN Foundation’s Shot@Life campaign. “By raising awareness, funding and asking members of Congress to support global immunization programs we can ensure that every child, no matter where they live, is given a shot at a healthy life.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7616651-shotatlife-united-nations-vaccines/
Consumers seeking locally sourced products can easily find one in an everyday pantry staple – vegetable oil, which is primarily 100 percent soybean oil made from soybeans grown in the U.S. Sales of vegetable oil support more than 550,000 U.S. soybean farmers who strive to leave the land in better shape than they found it for America’s next generation of farmers. “I work hard to help produce an ingredient that I am proud to serve to my own family, as well as families across the U.S.,” said United Soybean Board (USB) Chairman Bob Haselwood. “Every time you purchase vegetable oil, or soybean oil, you’re supporting local farmers.” Haselwood produces soybeans on his farm in Berryton, Kansas. Many retailers sell soybean oil primarily produced with U.S.-grown soybeans. This past summer, USB partnered with a large Midwest grocery retail chain with 200+ stores to emphasize the importance of knowing where food comes from and educate about the benefits of soybean oil. During this promotion, unit sales of the store brand vegetable oil rose more than 27 percent over the same time last year, and shoppers commented that they were more likely to purchase soybean oil knowing it’s a U.S.-grown product. To view the multimedia release go to: http://www.multivu.com/players/English/7689851-united-soybean-board-eat-local/
The St. Baldrick’s Foundation, a volunteer-powered charity dedicated to funding childhood cancer research, announces its Kids Are Special: Let’s Treat Them That Way national campaign. Focused on celebrating kids and giving them the happy childhoods they deserve, the campaign highlights the need for finding treatments that are specifically designed for kids with cancer.
With this bold new initiative, St. Baldrick’s looks to change the narrative around pediatric cancers, by showing kids as their truest selves – fun-loving, carefree, refreshingly honest, and always a little goofy. St. Baldrick’s puts the emphasis back on kids, while disempowering the label of “cancer.” All communication is strategically designed to remind us all that as adults we have the power to give kids happy childhoods free from cancer by helping to fund the best research worldwide. The campaign includes TV, print, radio, digital, and billboard placements featuring real kids doing kid-like things; from playing with their food to getting caught with paint on their faces, all with the message: Kids Are Special: Let’s Treat Them That Way.
To view the multimedia release go to:
http://www.multivu.com/players/English/7610752-st-baldricks-kids-are-special/
Whole You, a Mitsui Chemicals Company dedicated to offering innovative healthcare solutions to help those with sensory and physical mobility challenges experience life more fully, launched its Whole Day campaign video today. The video follows acclaimed photographer Bruce Hall, who has been legally-blind since birth, as he captures a celebration of the senses and movement.
“At Whole You we want nothing less than to change how people understand what it means to be healthy – we develop solutions that enable people to move, see, smell, taste and experience the world more fully than ever before,” said Hiromi Inagaki, chief innovation officer, Whole You. “The video with Bruce is an expression of this vision, a place where sensory or physical mobility challenges don’t hold us back, where we celebrate the senses and freedom of movement to have a deeper appreciation of a life lived beyond limitations.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7704351-whole-you-bruce-hall-campaign/
